Pretax income is the income that a company earns before paying income taxes. Biofrontera's pretax income for the
three
months ended in Mar. 2024 was $-10.44 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.08 Mil.
Biofrontera's pretax margin was -131.90%.
During the past 5 years, Biofrontera's highest Pretax Margin was -2.12%. The lowest was -156.25%. And the median was -57.95%.
Biofrontera Pre-Tax Income Historical Data
The historical data trend for Biofrontera's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biofrontera's Pre-Tax Income
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera's Pre-Tax Income Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Biofrontera's Pre-Tax Income falls into.
Biofrontera Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Biofrontera's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofrontera (NAS:BFRI) Pre-Tax Income Explanation
Biofrontera's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 5 years, Biofrontera's highest Pretax Margin was -2.12%. The lowest was -156.25%. And the median was -57.95%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofrontera Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Biofrontera's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BFRI has been successfully added to your 